TY - JOUR
T1 - United States critical illness and injury trials group
AU - Blum, James M.
AU - Morris, Peter E.
AU - Martin, Greg S.
AU - Gong, Michelle N.
AU - Bhagwanjee, Satish
AU - Cairns, Charles B.
AU - Cobb, J. Perren
N1 - Funding Information:
Funding/Support: This work was funded in part by the National Institutes of Health [Grants U13 GM083407, U01 HL108712] and the US Department of Health and Human Services [Contract HHSOl 0020 ll00062P].
Funding Information:
The United States Critical Illness and Injury Trials (USCIIT) Group created clinical research infrastructure to reduce the barriers to investigation for the critical illness and injury communities in the United States. 1 As an inclusive, grassroots “network of networks,” the USCIIT Group's dual missions are to foster investigator-initiated hypothesis testing and to develop recommendations for strategic plans at a national level. 2 The USCIIT Group was funded in 2008 by a National Institutes of Health (NIH) (National Institute of General Medical Science) meeting grant (U13) with four aims 3 :
PY - 2013/3
Y1 - 2013/3
N2 - The United States Critical Illness and Injury Trials (USCIIT) Group is an inclusive, grassroots "network of networks" with the dual missions of fostering investigator-initiated hypothesis testing and developing recommendations for strategic plans at a national level. The USCIIT Group's transformational approach enlists multidisciplinary investigative teams across institutions, critical illness and injury professional organizations, federal agencies that fund clinical and translational research, and industry partners. The USCIIT Group is endorsed by all major critical illness and injury professional organizations spanning the specialties of anesthesiology, emergency medicine, internal medicine, neurology, nursing, pediatrics, pharmacy and nutrition, surgery and trauma, and respiratory and physical therapy. Recent successes provide the opportunity to significantly increase the dialogue necessary to advance clinical and translational research on behalf of our community. More than 200 investigators are now involved across> 30 academic and community hospitals. Collectively, USCIIT Group investigators have enrolled > 10,000 patients from academic and community hospitals in studies during the last 3 years. To keep our readership "ahead of the curve," this article provides a vision for critical illness and injury research based on (1) programmatic organization of large-scale, multicentered collaborative studies and (2) annual strategic planning at a national scale across disciplines and stakeholders.
AB - The United States Critical Illness and Injury Trials (USCIIT) Group is an inclusive, grassroots "network of networks" with the dual missions of fostering investigator-initiated hypothesis testing and developing recommendations for strategic plans at a national level. The USCIIT Group's transformational approach enlists multidisciplinary investigative teams across institutions, critical illness and injury professional organizations, federal agencies that fund clinical and translational research, and industry partners. The USCIIT Group is endorsed by all major critical illness and injury professional organizations spanning the specialties of anesthesiology, emergency medicine, internal medicine, neurology, nursing, pediatrics, pharmacy and nutrition, surgery and trauma, and respiratory and physical therapy. Recent successes provide the opportunity to significantly increase the dialogue necessary to advance clinical and translational research on behalf of our community. More than 200 investigators are now involved across> 30 academic and community hospitals. Collectively, USCIIT Group investigators have enrolled > 10,000 patients from academic and community hospitals in studies during the last 3 years. To keep our readership "ahead of the curve," this article provides a vision for critical illness and injury research based on (1) programmatic organization of large-scale, multicentered collaborative studies and (2) annual strategic planning at a national scale across disciplines and stakeholders.
UR - http://www.scopus.com/inward/record.url?scp=84874968746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874968746&partnerID=8YFLogxK
U2 - 10.1378/chest.12-2287
DO - 10.1378/chest.12-2287
M3 - Article
C2 - 23460158
AN - SCOPUS:84874968746
SN - 0012-3692
VL - 143
SP - 808
EP - 813
JO - Diseases of the chest
JF - Diseases of the chest
IS - 3
ER -